ArticleCancer biology & medicine2025
IL-17A blockade alleviates immune checkpoint inhibitor-associated psoriasiform rash: preclinical and clinical responses.
Yuli Ruan, Mengde Shi, Yue Ma, Bojun Wang, Ming Ma, Tianjiao Dang, Yanqiao Zhang, Chao Liu
Abstract readLetter
In one paragraphArticle in Cancer biology & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Yuli Ruan *Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150001, China.
Mengde Shi *Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150001, China.
Yue Ma *Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150001, China.
Bojun WangDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150001, China.
Ming MaDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150001, China.
Tianjiao DangDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150001, China.
Yanqiao ZhangDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150001, China.ORCID 0000-0002-6206-8364 Chao LiuDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin 150001, China.ORCID 0009-0001-8104-6750 Funding
Beijing Xisike Clinical Oncology Research Foundation Y-HR2020MS-0900Key Project of Research and Development Plan in Heilongjiang Province 2022ZX06C01Key Project of Research and Development Plan in Heilongjiang Province JD2023SJ40National Cancer Center Climbing Fund NCC201908A03National Natural Science Foundation of China 82373372National Natural Science Foundation of China U22A20330
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
IL-17AImmune checkpoint inhibitorsimmune-related cutaneous adverse eventspsoriasiform rashsecukinumab
Identifiers
PMID41078009
PMCPMC12624807
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390